BiomX (PHGE) Total Liabilities (2018 - 2026)
BiomX (PHGE) posted Total Liabilities of $4.1 million for Q1 2026, down 41.68% sequentially from $7.1 million in Q4 2025, and down 90.95% YoY from $45.7 million in Q1 2025.
BiomX (PHGE) Total Liabilities (2018 - 2026) Analysis & Trends
BiomX has reported Total Liabilities for 9 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Total Liabilities fell 90.95% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 90.95% YoY) and the FY2025 annual result came in at $7.1 million, down 83.61% from the prior year.
- Total Liabilities declined to $4.1 million in Q1 2026 per PHGE's latest filing, from $7.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $68.7 million in Q1 2022 and troughed at $203000.0 in Q4 2022.
- A 5-year average of $34.5 million and a median of $38.0 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities sank 99.74% in 2022, then jumped 12229.56% in 2023.
- Over 5 years, Total Liabilities stood at $203000.0 in 2022, then surged by 12229.56% to $25.0 million in 2023, then jumped by 72.73% to $43.2 million in 2024, then tumbled by 83.61% to $7.1 million in 2025, then plunged by 41.68% to $4.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $4.1 million, $7.1 million, and $26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | 4.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.13 Mn |
| Dec 31, 2025 | 7.09 Mn |
| Sep 30, 2025 | 26.17 Mn |
| Jun 30, 2025 | 38.05 Mn |
| Mar 31, 2025 | 45.65 Mn |
| Dec 31, 2024 | 43.23 Mn |
| Sep 30, 2024 | 59.98 Mn |
| Jun 30, 2024 | 68.62 Mn |
| Mar 15, 2024 | 14.08 Mn |
| Dec 31, 2023 | 25.03 Mn |
| Sep 30, 2023 | 33.06 Mn |
| Jun 30, 2023 | 41.25 Mn |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 203,000.00 |
| Sep 30, 2022 | 51.90 Mn |
| Jun 30, 2022 | 58.38 Mn |
| Mar 31, 2022 | 68.74 Mn |
| Dec 31, 2021 | 77.99 Mn |
| Sep 30, 2021 | 81.80 Mn |
| Jun 30, 2021 | 61.65 Mn |